Carlene MacMillan, MD is VP, Clinical Innovation at Osmind, where she focuses on product and growth.
She has been the co-founder of Brooklyn Minds Psychiatry, a multidisciplinary team-based multi-site practice in the NYC Region with over 30 providers. She is a graduate of Harvard College and Harvard Medical School and completed her adult psychiatry residency and child and adolescent fellowship at Massachusetts General Hospital/McLean Hospital.
Dr. Macmillan has a long-standing interest in helping individuals with severe, persistent and complex mental illness live meaningful lives in their communities. She was previously an attending physician on the Trauma and Dissociative Unit at McLean Hospital. She has also held a faculty position at the NYU Langone School of Medicine and was the founding Medical Director of the Ellenhorn NYC Private Assertive Community Treatment Team.
In her work at Brooklyn Minds, she has built a robust deep TMS program over the past 4 years. Brooklyn Minds was one of the first practices in the country to offer deep TMS for OCD upon FDA clearance. As a member of the Clinical TMS Insurance Committee, she focuses primarily on advocating for appropriate OCD coverage policies as her team at Brooklyn Minds has been at the forefront of obtaining insurance coverage from commercial and Medicaid payers. Brooklyn Minds was also one of the first practices in NYC to offer esketamine for severe depression and suicidal thinking when it received FDA approval and is building a team within the practice devoted to increasing access and awareness of psychedelic medicine and psychedelic-assisted therapy.
Dr. MacMillan also serves as the Co-Chair of the American Academy of Child and Adolescent Psychiatry Consumer Issues Committee which publishes materials for patients and families on a wide range of mental health topics. She is a former member of the American Psychiatric Association Assembly and was very active in the Massachusetts Psychiatric Society throughout residency and fellowship.
Dr. MacMillan is passionate about increasing adoption and access to groundbreaking interventional psychiatric approaches including TMS and psychedelic medicine. She is frequently quoted in the popular press and maintains an active professional presence on various social media platforms from traditional platforms like Facebook and Twitter to novel platforms like Clubhouse where she goes by the name @psychiatrist and has been honored in the inaugural Creator First program. She uses these platforms to champion evidence-based approaches and innovations in psychiatry.
She believes increasing public awareness and acceptance of effective treatment and reducing stigma around mental illness is particularly important as we face a growing mental health crisis across the globe.